Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Indolent Non-Hodgkin Lymphoma × obinutuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 80 Lymphoma, Follicular 46 Lymphoma, Non-Hodgkin 33 Lymphoma 27 Lymphoma, Large B-Cell, Diffuse 23 Lymphoma, Mantle-Cell 21 Lymphoma, B-Cell, Marginal Zone 20 Lymphoma, B-Cell 16 Recurrence 13 Neoplasms 10 Leukemia 7 Leukemia, B-Cell 5 Burkitt Lymphoma 5 Leukemia, Hairy Cell 4 Waldenstrom Macroglobulinemia 3 Neoplasm, Residual 3 Melanoma 3 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Bronchiolitis Obliterans Syndrome 2 Uveal Melanoma 1 Urinary Bladder Neoplasms 1 Tumor Lysis Syndrome 1 Solid Tumors 1 Solid Cancers 1 Prostatic Neoplasms 1 Part1: Advanced B-cell Malignancies 1

Interventions

obinutuzumab 1 ibrutinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02689869 2021-05-07

Alternative

Ludwig-Maximilians - University of Munich

Phase 2 Unknown

Indolent Non-Hodgkin Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡